SYGNIS Pharma AG Says Stroke Drug AX200 Failed to Meet Study Goal

Sygnis Pharma AG’s experimental AX200 protein-based treatment for strokes failed to meet the primary goal of a mid-stage study, after a trial of the medication showed no difference for people treated with placebo. “The study recorded no clinical improvement and did not show any statistically significant difference,” the company said in a statement today. “Sygnis Pharma will continue to analyze the current data set and the new data that will become available in the weeks ahead.” The trial was based on 328 patients in Europe, the company said. The drug is the Heidelberg, Germany-based biotechnology company’s only product in development. Sygnis decided in October 2010 to cut its workforce in half as it adopted a strategy focused on getting AX200 to market.